Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 5/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | RBBP5 | Q15291 | 5/20 | 0.78 |
| ▸ | DPY30 | Q9C005 | 5/20 | 0.78 |
| ▸ | ASH2L | Q9UBL3 | 5/20 | 0.78 |
| ▸ | KRAS | P01116 | 8/20 | 0.40 |
| ▸ | MDM4 | O15151 | 4/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | FURIN | P09958 | 1/20 | 0.36 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15005758 | 1.00 | WDR5 (0.78) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23682876 | 1.00 | WDR5 (0.78) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL15004656 | 0.99 | WDR5 (0.79) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL20564850 | 0.99 | WDR5 (0.79) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL15004646 | 0.99 | WDR5 (0.79) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL15005735 | 0.99 | WDR5 (0.79) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL15005695 | 0.99 | WDR5 (0.79) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL20565531 | 0.99 | WDR5 (0.79) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL15004659 | 0.99 | WDR5 (0.79) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL20564489 | 0.98 | WDR5 (0.75) | WDR5KMT2ARBBP5DPY30ASH2L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | UNIV MICHIGAN REGENTS (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | UNIV MICHIGAN REGENTS (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2018213228-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-11-22 | — | — | WO | disclosed |
| US-8980838-B2 | Cyclized peptidomimetic small molecule inhibitors of the WDR5 and MLL1 interaction | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130150309-A1 | CYCLIZED PEPTIDOMIMETIC SMALL MOLECULE INHIBITORS OF THE WDR5 AND MLL1 INTERACTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2013082017-A1 | CYCLIZED PEPTIDOMIMETIC SMALL MOLECULE INHIBITORS OF THE WDR5 AND MLL1 INTERACTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | WDR5 1850/4885KMT2A 2202/4885RBBP5 822/4885 |
| US-20130150309-A1 | CYCLIZED PEPTIDOMIMETIC SMALL MOLECULE INHIBITORS OF THE WDR5 AND MLL1 INTERACTION | WDR5, WDR1, WDR77 | WDR5 1/4885KMT2A 37/4885RBBP5 14/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | WDR5 251/4885KMT2A 1091/4885RBBP5 18/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | WDR5 251/4885KMT2A 1091/4885RBBP5 18/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | WDR5 2281/4885KMT2A 851/4885RBBP5 571/4885 |
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | WDR5, MLLT1, WDR1 | WDR5 1/4885KMT2A 22/4885RBBP5 9/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | WDR5 3765/4885KMT2A 1662/4885RBBP5 290/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | WDR5 107/4885KMT2A 1612/4885RBBP5 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.